Michèle Beau‐Faller

4.5k citations

61 papers · 2.1k indexed · 1 hit paper · h-index 22

Impact in

Oncology top 2%
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
Pulmonary and Respiratory Medicine top 1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in

Pulmonary and Respiratory Medicine 53
- Lung Cancer Treatments and Mutations 52
- Lung Cancer Diagnosis and Treatment 16
Oncology 31
- Lung Cancer Research Studies 16
- Colorectal Cancer Treatments and Studies 8

Co-authors: Julien Mazières Marie Wislez Fabrice Barlési Denis Moro‐Sibilot Isabelle Rouquette Benjamin Besse Julie Milia Anne‐Claire Voegeli
Journals: Annals of Oncology (8 papers)Journal of Clinical Oncology (8 papers)Journal of Thoracic Oncology (6 papers)Clinical Cancer Research (3 papers)European Respiratory Journal (3 papers)
Partner nations: France Switzerland United States

In The Last Decade

Michèle Beau‐Faller

59 papers receiving 2.1k citations

Hit Papers

align trajectories log scale

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives 2013 · 489 citations

Peers

Countries citing papers authored by Michèle Beau‐Faller

Since Specialization

Citations

This map shows the geographic impact of Michèle Beau‐Faller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michèle Beau‐Faller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michèle Beau‐Faller more than expected).

Fields of papers citing papers by Michèle Beau‐Faller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michèle Beau‐Faller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michèle Beau‐Faller. The network helps show where Michèle Beau‐Faller may publish in the future.

Co-authors

The 25 scholars most cited alongside Michèle Beau‐Faller, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michèle Beau‐Faller Line = papers co-authored together Michèle Beau‐Faller links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer Biomedicines ·Carolina Castillo Larrea, Joseph Seitlinger, T Asako, Julien Demiselle, Ysia Idoux‐Gillet, Erwan Pencreach, Michèle Beau‐Faller, Véronique Lindner, Jean‐Marc Balloul, Éric Quéméneur, Hélène Burckel, G. Noël, Anne Olland, Florence Fioretti, Pierre‐Emmanuel Falcoz, Nadia Benkirane-Jessel, Guoqiang Hua	2023	2
2	PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project Lung Cancer ·Hélène Blons, Nicole Bly, Jean‐Philippe Merlio, D. Debieuvre, Florence de Fraipont, Clarisse Audigier-Valette, Fabienne Escande, S. Hominal, Tracey Rose, Toro Felipe, L’Houcine Ouafik, Denis Moro‐Sibilot, Antoinette Lemoine, Alexandra Langlais, Jeanne Lima de Oliveira, Franck Morin, P.-J. Souquet, Fabrice Barlési, Jacques Cadranel, Michèle Beau‐Faller	2020	7
3	Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study PLoS ONE ·Chutimon Jongruksavongkul, William B. Weeks, L’Houcine Ouafik, Isabelle Rouquette, Michèle Beau‐Faller, Antoinette Lemoine, Pierre‐Paul Bringuier, Anne‐Gaëlle Le Corroller, Fabrice Barlési, Bruno Ventelou	2020	8
4	Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project Lung Cancer ·Michèle Beau‐Faller, Erwan Pencreach, Charlotte Leduc, Hélène Blons, Jean‐Philippe Merlio, Pierre‐Paul Bringuier, Florence de Fraipont, Fabienne Escande, Antoinette Lemoine, L’Houcine Ouafik, Marc G. Denis, Paul Hofman, Roger Lacave, Samia Melaabi, Alexandra Langlais, Pascale Missy, Franck Morin, Denis Moro‐Sibilot, Fabrice Barlési, J. Cadranel	2019	13
5	High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study Journal of Thoracic Oncology ·Simon Baldacci, Martin Figeac, Martine Antoine, 高野優香, Zoulika Kherrouche, Philippe Jamme, Marie‐Christine Copin, David Tulasne, Isabelle Nanni, Michèle Beau‐Faller, Samia Melaabi, Guénaëlle Levallet, Élisabeth Quoix, Denis Moro‐Sibilot, S. Friard, Pascale Missy, Fabrice Barlési, Jacques Cadranel, Alexis B. Cortot	2019	16
6	Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases Journal of Thoracic Oncology ·Ronan Flippot, Pamela Biondani, Édouard Auclin, Xiaoyi Xi, Lizza Hendriks, Émilie Le Rhun, Charlotte Leduc, Michèle Beau‐Faller, Radj Gervais, Jordi Remón, Julien Adam, David Planchard, Pernelle Lavaud, Charles Naltet, Caroline Caramella, C. Le Péchoux, Ludovic Lacroix, Anas Gazzah, Laura Mezquita, Benjamin Besse	2019	22
7	Ultrasensitive detection of EGFR T790M mutation by droplet digital PCR (ddPCR) in TKI naïve non-small cell lung cancer (NSCLC) harboring EGFR mutation: Results of the nationwide program Biomarkers France of the French Cooperative Thoracic Intergroup (IFCT) Annals of Oncology ·Charlotte Leduc, Erwan Pencreach, J.P. Merlio, Tracey Rose, Florence de Fraipont, Fabienne Escande, Karime Tavares Lima da Silva, Gabrielle Jovana Antoniazi, Hélène Blons, Marc G. Denis, Paul Hofman, Roger Lacave, Samia Melaabi, Alexandra Langlais, Jeanne Lima de Oliveira, Franck Morin, Fabrice Barlési, Denis Moro‐Sibilot, J. Cadranel, Michèle Beau‐Faller	2017	0
8	OA10.06 Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study) Journal of Thoracic Oncology ·Nicolas Guibert, Fabrice Barlési, R. Descourt, H. Léna, Benjamin Besse, Michèle Beau‐Faller, Jean Mosser, Éric Pichon, Jean‐Philippe Merlio, L’Houcine Ouafik, F. Guichard, Bénédicte Mastroïanni, L. Moreau, S A Ivanova, Jean‐Christophe Sabourin, Antoinette Lemoine, Pascale Missy, Alexandra Langlais, Denis Moro‐Sibilot, Julien Mazières	2017	1
9	Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) Annals of Oncology ·Charlotte Leduc, Hélène Blons, Benjamin Besse, J.P. Merlio, D. Debieuvre, Antoinette Lemoine, I. Monnet, Damien Pouessel, P. P. Bringuier, M. Poudenx, Isabelle Rouquette, F. Vaylet, Franck Morin, Alexandra Langlais, Élisabeth Quoix, Gérard Zalcman, Denis Moro‐Sibilot, J. Cadranel, Michèle Beau‐Faller, Fabrice Barlési	2016	2
10	Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas† European Journal of Cardio-Thoracic Surgery ·Francesco Guerrera, Stéphane Renaud, Fabrizio Tabbò, Anne‐Claire Voegeli, Pier Luigi Filosso, M Legrain, Monica Boita, Mickaël Schaeffer, Michèle Beau‐Faller, Enrico Ruffini, Pierre‐Emmanuel Falcoz, Giorgio Inghirami, A Oliaro, Gilbert Massard	2016	15
11	Carcinomes bronchiques non à petites cellules (CBNPC) métastatiques, mutés ou réarrangés : comment déterminer la cible ? Revue des Maladies Respiratoires Actualités ·Michèle Beau‐Faller, Stéphane Renaud, Noëlle Weingertner, Véronique Lindner, Akbari Alvanagh, Gabriel Lloyd C. Malinay, M Legrain, Anne‐Claire Voegeli, J S. Bach, Erwan Pencreach, Marie Pierre Gaub, Achim Schneider, Éric Guérin	2015	0
12	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort Annals of Oncology ·Julien Mazières, Fabrice Barlési, Thomas Filleron, Benjamin Besse, I. Monnet, Michèle Beau‐Faller, Solange Peters, Éric Dansin, Martin Früh, Miklos Pless, Rafael Rosell, Marie Wislez, P. Fournel, Virginie Westeel, Federico Cappuzzo, Alexis B. Cortot, Denis Moro‐Sibilot, Julie Milia, Oliver Gautschi	2015	219
13	RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer Clinical Cancer Research ·Olivier Calvayrac, Anne Pradines, Isabelle Raymond‐Letron, Isabelle Rouquette, Emilie Bousquet, Valérie Lauwers‐Cancès, Thomas Filleron, J. Cadranel, Michèle Beau‐Faller, Juan F. Benfeldt, Julie Milia, Gilles Favre, Julien Mazières	2014	18
14	Role of hypoxia in epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) European Respiratory Journal ·Stéphane Renaud, Dominique Guénot, Pierre‐Emmanuel Falcoz, Gilbert Massard, Michèle Beau‐Faller	2014	7
15	Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung Lung Cancer ·Thibault Vieira, Martine Antoine, Anne-Marie Ruppert, Vincent Fallet, M. Duruisseaux, Etienne Giroux‐Leprieur, Virginie Poulot, Nathalie Rabbe, Sameir M. Ali Hamed, Michèle Beau‐Faller, Roger Lacave, A. Lavolé, Jacques Cadranel, Marie Wislez	2014	63
16	A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma Clinical Cancer Research ·Bob Weeden, Julien Laffaire, Paul Hofman, Michèle Beau‐Faller, Julien Mazières, Pierre Validire, Philippe Girard, Sophie Camilleri‐Broët, F. Vaylet, François Leroy-Ladurie, Jean‐Charles Soria, Pierre Fouret	2012	56
17	An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial Clinical Cancer Research ·Florence de Fraipont, Guénaëlle Levallet, Christian Créveuil, Emmanuel Bergot, Michèle Beau‐Faller, Mounia Mounawar, Nicolas Richard, Martine Antoine, Isabelle Rouquette, Marie‐Christine Favrot, D. Debieuvre, Denis Braun, Virginie Westeel, Élisabeth Quoix, Élisabeth Brambilla, Pierre Hainaut, Denis Moro‐Sibilot, Franck Morin, B. Milleron, Gérard Zalcman	2012	46
18	Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma Annals of Oncology ·Paul Hofman, Marius Ilié, Véronique Hofman, S. Roux, A. Valent, Alain Bernheim, Marco Alifano, François Leroy-Ladurie, F. Vaylet, Isabelle Rouquette, Pierre Validire, Michèle Beau‐Faller, E Rawlinson, Jean‐Charles Soria, P Fouret	2011	48
19	Un regard simple sur la biologie du cancer bronchique : MET Revue des Maladies Respiratoires ·Anne-Marie Ruppert, Michèle Beau‐Faller, L. Belmont, A. Lavolé, V. Gounant, Jacques Cadranel, Marie Wislez	2011	7
20	Genomic Aberrations in Lung Adenocarcinoma in Never Smokers PLoS ONE ·Bastien Job, Alain Bernheim, Michèle Beau‐Faller, Sophie Camilleri‐Broët, Philippe Girard, Paul Hofman, Julien Mazières, Manjusha V Chikkanagoudar, Ludovic Lacroix, Julien Laffaire, Philippe Dessen, Pierre Fouret, (unknown)	2010	54

About Michèle Beau‐Faller

Michèle Beau‐Faller is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Pathology and Forensic Medicine and Hepatology, having authored 61 papers that have together received 2.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Research Studies (16 papers), Lung Cancer Diagnosis and Treatment (16 papers), Cancer Genomics and Diagnostics (15 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (9 papers), Colorectal Cancer Treatments and Studies (8 papers), Genetic factors in colorectal cancer (6 papers) and RNA modifications and cancer (5 papers). The work is most often cited by research in Oncology (1.3k citations), Pulmonary and Respiratory Medicine (1.6k citations), Cancer Research (554 citations), Molecular Biology (758 citations) and Hepatology (84 citations). Michèle Beau‐Faller has collaborated with scholars based in France, Switzerland and United States. Frequent co-authors include Julien Mazières, Marie Wislez, Fabrice Barlési, Denis Moro‐Sibilot, Isabelle Rouquette, Benjamin Besse, Julie Milia, Anne‐Claire Voegeli, Alexis B. Cortot and Gilbert Massard. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology, Clinical Cancer Research and European Respiratory Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact